Portfolio company
Areteia Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
The company develops an oral medication for patients with eosinophilic asthma to reduce inflammation and manage their condition.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Kinaset Therapeutics
This biopharmaceutical company develops inhaled anti-inflammatory therapies to treat patients with severe asthma and other respiratory diseases.
Aiolos Bio
This biopharmaceutical company develops monoclonal antibody therapies for patients suffering from respiratory and inflammatory conditions such as moderate-to-severe asthma.
Upstream Bio
The company develops monoclonal antibody therapies for patients with chronic inflammatory and respiratory diseases, including asthma and chronic rhinosinusitis.
AirNexis Therapeutics
This company develops inhaled small molecule medicines to treat chronic obstructive pulmonary disease for patients with respiratory conditions.
Third Harmonic Bio
This biopharmaceutical company develops oral small-molecule inhibitors for patients with mast-cell-mediated inflammatory diseases such as chronic urticaria and asthma.
Altesa BioSciences
This company develops antiviral medicines for patients with chronic lung diseases such as COPD and asthma to prevent respiratory infections and illness flare-ups.
Attenua
This company develops small-molecule medicines for patients suffering from chronic respiratory disorders, particularly chronic cough.
Apieron
This company develops biosensor devices to monitor exhaled nitric oxide for asthma management in patients and clinical settings.